{"hands_on_practices": [{"introduction": "The definitive diagnosis of gastroparesis hinges on the gastric emptying scintigraphy (GES) study, but its accuracy is critically dependent on controlling for confounding variables. This first exercise [@problem_id:4837855] challenges you to apply foundational physiologic principles to a complex clinical scenario, emphasizing the crucial step of ensuring test validity before confirming a diagnosis. Addressing factors like hyperglycemia and medication effects is paramount to distinguish true idiopathic or diabetic gastroparesis from reversible gastric slowing.", "problem": "A $52$-year-old woman with type $1$ diabetes mellitus for $22$ years presents with $9$ months of early satiety, postprandial fullness, nausea, abdominal bloating, and intermittent non-bilious emesis of undigested food occurring $\\approx 6-8$ hours after meals. She reports unintentional weight loss of $6$ kg. She also describes epigastric burning pain relieved transiently by food. She has painful diabetic neuropathy treated with oxycodone $10$ mg every $6$ hours for the past $6$ months. A trial of a proton pump inhibitor (PPI) at standard dose for $8$ weeks did not improve her symptoms. On examination, she is mildly orthostatic. Laboratory testing shows serum potassium $3.2$ mEq/L, hemoglobin within reference range, thyroid-stimulating hormone within reference range, Hemoglobin A1c (A1c) $9.4\\%$, and a random serum glucose of $288$ mg/dL. Esophagogastroduodenoscopy (EGD) shows no mechanical obstruction, but there is retained food in the stomach after an overnight fast; biopsies are negative for Helicobacter pylori. Abdominal computed tomography with contrast is normal.\n\nStarting from fundamental definitions and well-established physiologic facts that govern gastric motor function and diagnostic test validity, determine the most appropriate next step in management that applies an evidence-based algorithm to suspected diabetic gastroparesis in the presence of overlapping dyspeptic symptoms and chronic opioid exposure.\n\nWhich of the following is the best next step?\n\nA. Proceed with a $2$-hour solid-phase gastric emptying scintigraphy (GES) now while the patient continues all home medications to confirm delayed gastric emptying\n\nB. Discontinue opioids and other motility-altering agents for $48-72$ hours, correct hypokalemia, optimize day-of-test glucose to less than $180-200$ mg/dL, then obtain a standardized $4$-hour solid-phase GES; begin small, frequent, low-fat, low-fiber meals pending results\n\nC. Initiate metoclopramide $10$ mg four times daily immediately and continue indefinitely if symptomatic improvement occurs, foregoing further diagnostic testing because retained food on EGD is sufficient\n\nD. Escalate to high-dose PPI and initiate Helicobacter pylori eradication therapy, reassessing in $8$ weeks, while maintaining current opioid regimen\n\nE. Refer directly for gastric per-oral endoscopic pyloromyotomy (G-POEM) because retained food on EGD establishes the diagnosis of gastroparesis and predicts response to pyloric intervention", "solution": "The problem statement describes a $52$-year-old woman with a history of long-standing type $1$ diabetes mellitus presenting with symptoms highly suggestive of gastroparesis. The task is to determine the most appropriate next step in management based on fundamental principles of physiology and evidence-based diagnostic algorithms.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n-   **Patient Profile:** $52$-year-old woman.\n-   **Chronic Conditions:** Type $1$ diabetes mellitus for $22$ years; painful diabetic neuropathy.\n-   **Symptoms:** $9$-month history of early satiety, postprandial fullness, nausea, abdominal bloating, intermittent non-bilious emesis of undigested food occurring $\\approx 6-8$ hours after meals; unintentional weight loss of $6$ kg; epigastric burning pain relieved transiently by food.\n-   **Medications:** Oxycodone $10$ mg every $6$ hours for the past $6$ months; failed $8$-week trial of a standard-dose proton pump inhibitor (PPI).\n-   **Physical Examination:** Mildly orthostatic.\n-   **Laboratory Data:** Serum potassium $3.2$ mEq/L; Hemoglobin A1c (A1c) $9.4\\%$; random serum glucose $288$ mg/dL; hemoglobin and thyroid-stimulating hormone within reference range.\n-   **Procedural/Imaging Data:** Esophagogastroduodenoscopy (EGD) showed no mechanical obstruction and retained food after an overnight fast, with biopsies negative for *Helicobacter pylori*. Abdominal computed tomography (CT) with contrast was normal.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, well-posed, and objective.\n-   **Scientific Grounding:** The clinical presentation is a classic scenario for suspected diabetic gastroparesis. The provided history, symptoms, laboratory values (hyperglycemia, hypokalemia), medication list (opioids), and results of the initial workup (EGD, CT) are all consistent with established medical knowledge and practice in gastroenterology and endocrinology. The workup correctly follows the initial step of excluding mechanical obstruction as a cause for the patient's symptoms.\n-   **Well-Posedness:** The problem provides sufficient, non-contradictory information to apply a standard diagnostic algorithm for gastroparesis. The question asks for the \"best next step,\" which requires integrating multiple clinical variables to arrive at a logical and evidence-based decision.\n-   **Objectivity:** The problem is described using precise, standard clinical terminology, free from subjective or ambiguous language.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. A full solution will be derived.\n\n### Derivation of Solution\n\nThe definitive diagnosis of gastroparesis requires the fulfillment of two criteria: (1) the presence of characteristic symptoms, and (2) objective demonstration of delayed gastric emptying in the absence of mechanical obstruction.\n\n1.  **Exclusion of Mechanical Obstruction:** The patient has undergone both an EGD and an abdominal CT scan, which have effectively ruled out a mechanical obstruction (e.g., pyloric stenosis, malignancy, or external compression) as the cause of her symptoms. The finding of retained food in the stomach on EGD is highly suggestive of a motility disorder but is not, by itself, diagnostic of gastroparesis.\n\n2.  **Confirmation of Delayed Gastric Emptying:** The gold standard for objectively measuring and confirming delayed gastric emptying is **gastric emptying scintigraphy (GES)**. Therefore, obtaining a GES is the necessary next diagnostic step.\n\n3.  **Ensuring the Validity of Gastric Emptying Scintigraphy:** The validity of a GES study is critically dependent on controlling for variables known to influence gastric motor function. Proceeding with the test without addressing these confounders can lead to an erroneous diagnosis. Key factors in this patient's case include:\n    -   **Pharmacologic Agents:** The patient is taking oxycodone, an opioid. Opioids are well-known to inhibit gastric motility and can induce a clinical picture identical to gastroparesis. To differentiate between diabetic gastroparesis and opioid-induced gastric dysmotility, opioids must be discontinued for a sufficient period before the GES, typically for at least $48-72$ hours.\n    -   **Metabolic State (Hyperglycemia):** Acute hyperglycemia, particularly serum glucose levels exceeding $\\approx 275$ mg/dL, independently slows gastric emptying. Performing a GES in a hyperglycemic state can produce a false-positive result, incorrectly attributing the delay to an intrinsic motility disorder when it is a transient effect of high blood sugar. Guidelines recommend that serum glucose be controlled to a level less than $180-200$ mg/dL on the day of the study. The patient's random glucose is $288$ mg/dL and A1c is $9.4\\%$, indicating that her glycemic control is poor and must be optimized for a valid test.\n    -   **Electrolyte Imbalance:** The patient's serum potassium is $3.2$ mEq/L, indicating hypokalemia. Hypokalemia can impair smooth muscle contractility throughout the gastrointestinal tract, potentially contributing to delayed gastric emptying. This electrolyte abnormality should be corrected.\n\n4.  **Standard GES Protocol:** For maximal sensitivity and specificity, the GES must adhere to a standardized protocol. This includes a low-fat, solid-phase meal (e.g., egg-white based) and imaging at multiple time points, continuing for a minimum of $4$ hours. Shorter protocols (e.g., $2$ hours) have been shown to have unacceptably low sensitivity.\n\n5.  **Initial Management:** While awaiting definitive diagnostic testing, it is appropriate to initiate first-line, low-risk management strategies. The cornerstone of gastroparesis management is dietary modification, consisting of small, frequent meals that are low in fat and insoluble fiber, as both fat and fiber delay gastric emptying.\n\n**Conclusion of Derivation:** The most appropriate next step is to prepare the patient for a valid diagnostic study while initiating conservative management. This involves discontinuing confounding medications, correcting metabolic and electrolyte disturbances, scheduling a standardized $4$-hour GES, and providing dietary counseling.\n\n### Evaluation of Options\n\n**A. Proceed with a $2$-hour solid-phase gastric emptying scintigraphy (GES) now while the patient continues all home medications to confirm delayed gastric emptying**\n- **Analysis:** This option is incorrect for three primary reasons. First, a $2$-hour GES is an outdated and insufficiently sensitive protocol; a $4$-hour study is the current standard of care. Second, performing the study while the patient continues oxycodone would render the results uninterpretable, as any observed delay could be due to the opioid rather than underlying diabetic gastroparesis. Third, not addressing the acute hyperglycemia (random glucose $288$ mg/dL) would also confound the results.\n- **Verdict:** Incorrect.\n\n**B. Discontinue opioids and other motility-altering agents for $48-72$ hours, correct hypokalemia, optimize day-of-test glucose to less than $180-200$ mg/dL, then obtain a standardized $4$-hour solid-phase GES; begin small, frequent, low-fat, low-fiber meals pending results**\n- **Analysis:** This option systematically addresses all necessary components of a correct diagnostic and initial management plan. It calls for (1) controlling for all major confounders (opioids, hyperglycemia, hypokalemia), (2) using the correct, standardized diagnostic test ($4$-hour solid-phase GES), and (3) initiating the appropriate first-line therapy (dietary modification) in the interim. This approach is consistent with all established evidence-based guidelines.\n- **Verdict:** Correct.\n\n**C. Initiate metoclopramide $10$ mg four times daily immediately and continue indefinitely if symptomatic improvement occurs, foregoing further diagnostic testing because retained food on EGD is sufficient**\n- **Analysis:** This option is flawed. First, it relies on an insufficient diagnostic basis; retained food on EGD is not a substitute for a formal GES. Second, it proposes the immediate and indefinite use of metoclopramide, a drug with a significant risk of serious adverse effects, including a Food and Drug Administration (FDA) black box warning for tardive dyskinesia. Its use is generally restricted to confirmed cases and for the shortest possible duration (less than $12$ weeks). Treating empirically without a confirmed diagnosis and ignoring reversible causes (opioids, hyperglycemia) is medically inappropriate.\n- **Verdict:** Incorrect.\n\n**D. Escalate to high-dose PPI and initiate Helicobacter pylori eradication therapy, reassessing in $8$ weeks, while maintaining current opioid regimen**\n- **Analysis:** This approach is not logical. The patient has already failed an $8$-week course of a standard-dose PPI, making a primary acid-related disorder less likely. More importantly, EGD biopsies were explicitly negative for *H. pylori*, so eradication therapy is not indicated. Finally, maintaining the opioid regimen ignores a very likely contributor to the patient's symptoms.\n- **Verdict:** Incorrect.\n\n**E. Refer directly for gastric per-oral endoscopic pyloromyotomy (G-POEM) because retained food on EGD establishes the diagnosis of gastroparesis and predicts response to pyloric intervention**\n- **Analysis:** This is an overly aggressive and premature action. G-POEM is an invasive, third-line therapy for refractory gastroparesis, not an initial treatment. The diagnosis has not yet been formally established with a GES. Furthermore, reversible contributors like opioid use and hyperglycemia must be addressed before any irreversible procedure is considered. Leaping to an invasive intervention without a complete diagnostic workup and a trial of medical and dietary therapy is a violation of the standard of care.\n- **Verdict:** Incorrect.", "answer": "$$\\boxed{B}$$", "id": "4837855"}, {"introduction": "Once gastroparesis is diagnosed, therapeutic selection requires a careful balancing of efficacy and safety, particularly in patients with comorbidities. This practice [@problem_id:4837695] presents a high-stakes scenario involving a patient with refractory symptoms and a significant risk for cardiac arrhythmia due to a prolonged QTc interval. Navigating this challenge correctly involves a systematic approach to risk mitigation and knowledge of the nuanced safety profiles of different prokinetic agents.", "problem": "A patient with symptomatic gastroparesis presents for therapy selection. A $58$-year-old woman with long-standing insulin-dependent diabetes mellitus ($30$ years) has recurrent postprandial fullness, early satiety, and vomiting despite dietary modification, small frequent meals, and optimization of blood glucose with continuous subcutaneous insulin infusion. Gastric emptying scintigraphy shows retained solid meal content of $65\\%$ at $4$ hours. She previously had a trial of metoclopramide that was discontinued due to acute dystonia and akathisia. Current medications include ondansetron $8$ $\\mathrm{mg}$ as needed, nortriptyline $25$ $\\mathrm{mg}$ nightly for neuropathic pain, and domperidone obtained abroad. Electrocardiogram demonstrates a corrected QT interval (QTc) of $520$ $\\mathrm{ms}$ calculated by the Bazett formula. Laboratory evaluation shows serum potassium $K^+ = 3.2$ $\\mathrm{mEq/L}$ and magnesium $Mg^{2+} = 1.5$ $\\mathrm{mg/dL}$. There is no evidence of mechanical obstruction on prior endoscopy.\n\nBased on fundamental principles of risk mitigation for drug-induced ventricular arrhythmias and stepwise management of gastroparesis, which of the following is the most appropriate next therapeutic step to improve gastric emptying while minimizing arrhythmia risk in this patient who is intolerant of metoclopramide and has a prolonged QTc?\n\nA. Initiate intravenous erythromycin for $3$ days followed by oral maintenance therapy.\n\nB. Start prucalopride as a prokinetic and discontinue QT-prolonging agents, with electrolyte repletion; if symptoms persist, consider jejunal feeding.\n\nC. Enroll the patient in a domperidone Investigational New Drug program and proceed if QTc remains below $550$ $\\mathrm{ms}$.\n\nD. Refer for immediate implantation of a gastric electrical stimulation device.\n\nE. Begin mirtazapine for nausea and continue ondansetron for breakthrough symptoms.", "solution": "The core of this problem is to select a therapeutic plan for a patient with severe, symptomatic gastroparesis who is at extremely high risk for a life-threatening cardiac arrhythmia. The immediate priority must be risk mitigation.\n\n**1. Assessment of Arrhythmia Risk:**\nThe patient presents with multiple major risk factors for Torsades de Pointes (TdP), a polymorphic ventricular tachycardia that can cause sudden cardiac death:\n-   **Severely Prolonged QTc Interval:** A QTc of $520$ ms is well above the high-risk threshold of $500$ ms.\n-   **Electrolyte Abnormalities:** Both hypokalemia ($K^+ = 3.2$ mEq/L) and hypomagnesemia ($Mg^{2+} = 1.5$ mg/dL) are present. These electrolyte disturbances independently prolong the QT interval and potentiate the arrhythmogenic effects of QT-prolonging medications by impairing the function of cardiac potassium channels (e.g., IKr).\n-   **Polypharmacy with QT-Prolonging Drugs:** The patient is taking at least three medications known to prolong the QT interval:\n    -   **Domperidone:** A dopamine antagonist with a well-documented association with QT prolongation and sudden cardiac death.\n    -   **Ondansetron:** A serotonin $5-HT_3$ antagonist.\n    -   **Nortriptyline:** A tricyclic antidepressant.\n-   **Female Sex:** An additional independent risk factor.\n\nGiven this constellation of findings, the highest priority is to immediately and aggressively reduce the patient's risk of TdP. This must precede or be concurrent with any attempt to modify prokinetic therapy.\n\n**2. Stepwise Management of Gastroparesis:**\nThe patient has severe gastroparesis (65% retention at 4 hours) and has failed dietary changes, glycemic control, and is intolerant to metoclopramide. The next steps in management involve considering alternative prokinetics, symptomatic control, and, if those fail, nutritional support or invasive procedures.\n\n**3. Evaluation of Therapeutic Options:**\n\n**A. Initiate intravenous erythromycin for $3$ days followed by oral maintenance therapy.**\n-   **Analysis:** Erythromycin is a potent prokinetic but is also a strong inhibitor of the IKr potassium channel and a well-known cause of QT prolongation and TdP. Administering it to this patient would be extremely dangerous and is contraindicated. Furthermore, its prokinetic effect is limited by rapid tachyphylaxis, making oral maintenance therapy largely ineffective.\n-   **Verdict:** Incorrect and unsafe.\n\n**B. Start prucalopride as a prokinetic and discontinue QT-prolonging agents, with electrolyte repletion; if symptoms persist, consider jejunal feeding.**\n-   **Analysis:** This option represents the correct, multi-step approach.\n    -   **Safety First:** It correctly prioritizes discontinuing the offending QT-prolonging agents (domperidone, ondansetron, nortriptyline) and repleting potassium and magnesium. This is the essential first step to mitigate arrhythmia risk.\n    -   **Safe Prokinetic Choice:** It proposes starting prucalopride. As a highly selective serotonin $5-HT_4$ receptor agonist, prucalopride has been shown in extensive studies to lack a clinically significant effect on the QT interval, making it an ideal choice for a prokinetic in this high-risk patient.\n    -   **Correct Algorithm:** It correctly identifies the next step in the management hierarchy for refractory gastroparesis: if optimized medical therapy with a safe agent fails, the focus shifts to ensuring nutrition via post-pyloric (jejunal) feeding.\n-   **Verdict:** Correct, safe, and follows evidence-based guidelines.\n\n**C. Enroll the patient in a domperidone Investigational New Drug program and proceed if QTc remains below $550$ ms.**\n-   **Analysis:** This is incorrect and dangerous. The patient is already taking domperidone, and her QTc is already at a critical level of $520$ ms. Continuing this drug is contributing to the risk. Accepting a QTc up to $550$ ms is clinically indefensible. The primary goal should be to *lower* the QTc to a safer range ($470-480$ ms), not to tolerate a dangerously high value.\n-   **Verdict:** Incorrect.\n\n**D. Refer for immediate implantation of a gastric electrical stimulation device.**\n-   **Analysis:** Gastric electrical stimulation (GES) is an invasive therapy reserved for patients with drug-refractory nausea and vomiting from gastroparesis. This patient has not yet had an adequate and safe trial of medical therapy. It is premature to escalate to surgery before optimizing medical management (including correcting the unsafe regimen) and considering less invasive options like enteral nutritional support.\n-   **Verdict:** Incorrect and premature.\n\n**E. Begin mirtazapine for nausea and continue ondansetron for breakthrough symptoms.**\n-   **Analysis:** Mirtazapine can be a useful antiemetic in gastroparesis and has a lower QT prolongation risk than tricyclics. However, this option explicitly advises continuing ondansetron, a known QT-prolonging drug. It fails to address the full scope of the problem by not discontinuing all offending agents (especially domperidone and nortriptyline) and not mentioning electrolyte repletion. This is an incomplete and therefore unsafe plan.\n-   **Verdict:** Incorrect.", "answer": "$$\\boxed{B}$$", "id": "4837695"}, {"introduction": "For patients with severe, refractory gastroparesis, ensuring adequate nutrition while bypassing the dysfunctional stomach is a primary goal, often achieved through post-pyloric enteral feeding. This final practice [@problem_id:4837746] moves from diagnostics and pharmacology to the practicalities of nutritional support. By starting from the first principles of energy balance, you will derive the infusion rate required to meet a patient's metabolic needs, a fundamental calculation in clinical nutrition.", "problem": "A patient with severe diabetic gastroparesis has refractory symptoms and has been transitioned to exclusive continuous post-pyloric jejunal feeding to bypass impaired gastric emptying. The nutrition team sets a daily energy delivery target of $1{,}800$ kilocalories based on basal energy expenditure and clinical stress factors. The formula selected has an energy density of $1.2$ kilocalories per milliliter. Continuous infusion is planned over $24$ hours without scheduled interruptions to minimize gastric residuals and aspiration risk.\n\nStarting from first principles of energy balance and flow, derive the continuous jejunal feed rate that will meet the daily energy target. Use the following bases:\n\n- Energy balance: total daily energy delivered $E_{d}$ equals the product of formula energy density $\\rho_{E}$ and total daily volume $V$, so $E_{d} = \\rho_{E} \\cdot V$.\n- Flow definition: for continuous infusion, total volume $V$ equals the product of constant rate $r$ and duration $T$, so $V = r \\cdot T$.\n\nCombine these to obtain an expression for the required infusion rate $r$ and compute the numeric value for the parameters given. Express your final answer in milliliters per hour. Round your answer to three significant figures.", "solution": "The problem statement is subjected to validation before proceeding with a solution.\n\n**Step 1: Extract Givens**\n- Daily energy delivery target: $E_{d} = 1{,}800$ kilocalories.\n- Formula energy density: $\\rho_{E} = 1.2$ kilocalories per milliliter.\n- Continuous infusion duration: $T = 24$ hours.\n- Energy balance equation: $E_{d} = \\rho_{E} \\cdot V$, where $V$ is the total daily volume.\n- Flow definition equation: $V = r \\cdot T$, where $r$ is the constant infusion rate.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding**: The problem is grounded in fundamental principles of energy balance and fluid dynamics (flow rate). The context, enteral nutrition for gastroparesis, and the provided numerical values are standard and realistic within the field of clinical nutrition and internal medicine.\n- **Well-Posedness**: The problem is well-posed. It provides two equations and all necessary constants to solve for the single unknown variable, the infusion rate $r$. The setup is self-contained and sufficient for a unique solution.\n- **Objectivity**: The problem is stated in objective, precise, and clinical language, free of ambiguity or subjective claims.\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid as it is scientifically grounded, well-posed, and objective. It contains no logical contradictions, missing information, or unscientific premises. Therefore, a solution will be derived.\n\n**Derivation of the Infusion Rate**\n\nThe problem requires the derivation of the continuous jejunal feed rate, denoted by $r$, starting from two fundamental principles.\n\nThe first principle is the energy balance, which states that the total daily energy delivered, $E_{d}$, is the product of the formula's energy density, $\\rho_{E}$, and the total volume of formula infused, $V$. This relationship is given as:\n$$E_{d} = \\rho_{E} \\cdot V \\quad (*)$$\n\nThe second principle defines the total volume delivered under a continuous, constant flow. The total volume, $V$, is the product of the constant infusion rate, $r$, and the total duration of the infusion, $T$. This relationship is given as:\n$$V = r \\cdot T \\quad (**)$$\n\nOur objective is to find an expression for the rate $r$. The two equations are linked by the common variable $V$. We can solve for $V$ in the first equation and substitute it into the second. From equation $(*)$, we can isolate the total volume $V$:\n$$V = \\frac{E_{d}}{\\rho_{E}}$$\n\nNow, we substitute this expression for $V$ into equation $(**)$:\n$$\\frac{E_{d}}{\\rho_{E}} = r \\cdot T$$\n\nTo find the infusion rate $r$, we rearrange the equation by dividing both sides by the duration $T$:\n$$r = \\frac{E_{d}}{\\rho_{E} \\cdot T}$$\n\nThis equation provides the required continuous infusion rate $r$ in terms of the daily energy target $E_{d}$, the formula's energy density $\\rho_{E}$, and the total infusion time $T$.\n\nNow, we will substitute the given numerical values into this derived expression.\nThe given parameters are:\n- $E_{d} = 1800 \\text{ kcal}$\n- $\\rho_{E} = 1.2 \\frac{\\text{kcal}}{\\text{mL}}$\n- $T = 24 \\text{ h}$\n\nSubstituting these values yields:\n$$r = \\frac{1800 \\text{ kcal}}{1.2 \\frac{\\text{kcal}}{\\text{mL}} \\cdot 24 \\text{ h}}$$\n\nFirst, we calculate the denominator:\n$$1.2 \\cdot 24 = 28.8$$\nSo the expression becomes:\n$$r = \\frac{1800}{28.8} \\frac{\\text{kcal}}{\\frac{\\text{kcal}}{\\text{mL}} \\cdot \\text{h}}$$\n\nThe units simplify as:\n$$\\frac{\\text{kcal}}{\\frac{\\text{kcal}}{\\text{mL}} \\cdot \\text{h}} = \\frac{\\text{kcal} \\cdot \\text{mL}}{\\text{kcal} \\cdot \\text{h}} = \\frac{\\text{mL}}{\\text{h}}$$\nThis confirms that the resulting rate will be in the desired units of milliliters per hour.\n\nNow, we perform the numerical calculation:\n$$r = \\frac{1800}{28.8} = 62.5$$\n\nThe problem requires the answer to be rounded to three significant figures. The calculated value $62.5$ already has three significant figures ($6$, $2$, and $5$), so no further rounding is necessary.\nThe required continuous jejunal feed rate is $62.5$ milliliters per hour.", "answer": "$$\\boxed{62.5}$$", "id": "4837746"}]}